Salcedo-Hernández MJ, Aguilar-Ríos EA, Delgado-Nuño JE, Gómez-Andrade AJ, Ordaz-Contreras A, Vizcaíno-Cortez ZG, Cruz-Sandoval G, Villaseñor-Padilla JL, Centeno-Valadez D, Echeverría-González G, Rodríguez-Jiménez NA

Idioma: Español
Referencias bibliográficas: 31
Paginas: 11-16
Archivo PDF: 296.01 Kb.

RESUMEN

La espondilitis anquilosante (EA) es una enfermedad inflamatoria autoinmune que afecta a las articulaciones sacroiliacas y a la columna lumbar. Además de las manifestaciones articulares, los pacientes con EA presentan afecciones extra-articulares, de las cuales la afección cardiaca llega a presentarse en el 30%. Las manifestaciones de la afección cardiaca en EA más frecuentes son la enfermedad valvular cardiaca, las anomalías de la conducción y la raíz aórtica. La enfermedad valvular cardiaca se caracteriza por el engrosamiento de las válvulas, la regurgitación, disfunción diastólica y/o sistólica, fibrosis, etc. El objetivo de esta revisión fue abordar la frecuencia de afección valvular cardiaca, sus diferentes manifestaciones y la relación de los tratamientos en EA.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007; 369 (9570): 1379-1390.

2. Khan MA, Ball EJ. Genetic aspects of ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2002; 16 (4): 675-690.

3. Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002; 136 (12): 896-907.

4. Peláez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl. 2011; 86: 3-8.

5. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008; 67 (7): 955-959.

6. Goupille P. Psoriatic arthritis. Joint Bone Spine. 2005; 72 (6): 466-470.

7. De Keyser F, Mielants H. The gut in ankylosing spondylitis and other spondyloarthropathies: inflammation beneath the surface. J Rheumatol. 2003; 30 (11): 2306-2307.

8. Roldan CA. Valvular and coronary heart disease in systemic inflammatory diseases: Systemic Disorders in heart disease. Heart. 2008; 94 (8): 1089-1101.

9. Brunner F, Kunz A, Weber U, Kissling R. Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population? Clin Rheumatol. 2006; 25 (1): 24-29.

10. Ho HH, Yeh SJ, Tsai WP, Wang CM, Chen JY. Paroxysmal supraventricular tachycardia and Wolff-Parkinson-White syndrome in ankylosing spondylitis: a large cohort observation study and literature review. Semin Arthritis Rheum. 2012; 42 (3): 246-253.

11. Geirsson AJ, Eyjolfsdottir H, Bjornsdottir G, Kristjansson K, Gudbjornsson B. Prevalence and clinical characteristics of ankylosing spondylitis in Iceland - a nationwide study. Clin Exp Rheumatol. 2010; 28 (3): 333-340.

12. Letters to the Editor. Int J Rheum Dis. 2011; 14 (4): e56-e58.

13. Bulkley BH, Roberts WC. Ankylosing spondylitis and aortic regurgitation. Description of the characteristic cardiovascular lesion from study of eight necropsy patients. Circulation. 1973; 48 (5): 1014-1027.

14. O’Neill TW, Bresnihan B. The heart in ankylosing spondylitis. Ann Rheum Dis. 1992; 51 (6): 705-706.

15. Khan MA. Ankylosing spondylitis: clinical features. In: Klippel JH, Dieppe PA (eds). Rheumatology. St. Louis: Mosby; 1994; 25: 1-10.

16. Roldan CA, Chavez J, Wiest PW, Qualls CR, Crawford MH. Aortic root disease and valve disease associated with ankylosing spondylitis. J Am Coll Cardiol. 1998; 32 (5): 1397-1404.

17. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006; 33 (11): 2167-2172.

18. Szabo SM, Levy AR, Rao SR, Kirbach SE, Lacaille D, Cifaldi M et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011; 63 (11): 3294-3304.

19. LaBresh KA, Lally EV, Sharma SC, Ho G Jr. Two-dimensional echocardiographic detection of preclinical aortic root abnormalities in rheumatoid variant diseases. Am J Med. 1985; 78 (6 Pt 1): 908-912.

20. Mohammadi H, Babaie F, Hemmatzadeh M, Azizi G, Hajaliloo M, Ebrahimi AA et al. Evaluation of ERAP1 gene single nucleotide polymorphism in impressing the inflammatory cytokine profile of ankylosing spondylitis patients. Iran J Allergy Asthma Immunol. 2018; 17 (5): 464-474.

21. Qaiyumi S, Hassan ZU, Toone E. Seronegative spondyloarthropathies in lone aortic insufficiency. Arch Intern Med. 1985; 145 (5): 822-824.

22. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis. 2006; 65 (4): 423-432.

23. Peters MJ, Visman I, Nielen MM, Van Dillen N, Verheij RA, van der Horst-Bruinsma IE et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis. 2010; 69 (3): 579-581.

24. Akkoc N, van der Linden S, Khan MA. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Clin Rheumatol. 2006; 20 (3): 539-557.

25. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford). 2007; 46 (9): 1450-1453.

26. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum. 2004; 34 (3): 585-592.

27. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010; 69 (2): 325-331.

28. Stamp LK, O’Donnell JL. HLA-B27 associated spondyloarthropathy, vasculitis, and amyloid enteropathy: response to infliximab. J Rheumatol. 2005; 32 (2): 382-385.

29. Rawasia WF, Khan MS, Usman MS, Siddiqi TJ, Mujeeb FA, Chundrigar M et al. Safety and efficacy of transcatheter aortic valve replacement for native aortic valve regurgitation: A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2019; 93 (2): 345-353.

30. Vaglio A, Palmisano A, Corradi D, Salvarani C, Buzio C. Retroperitoneal fibrosis: evolving concepts. Rheum Dis Clin North Am. 2007; 33 (4): 803-817, vi-vii.

31. Salvarani C, Pipitone N, Versari A, Vaglio A, Serafini D, Bajocchi G et al. Positron emission tomography (PET): evaluation of chronic periaortitis. Arthritis Rheum. 2005; 53 (2): 298-303.